TOOLS AND RESOURCES

CARE project resources

CARE Datasets

Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity
This report describes the most relevant results of screening a drug repurposing library consisting of ~5500 FDA-approved drugs and clinical candidates that have passed phase I studies for activity against SARS-CoV-2.
Public dataset, availalbe on Zenodo

Access to dataset

CARE Public deliverables & public summaries

D2.2 – A HTS assay for the RTC under a 384 well plate format
This report describes a robust Coronavirus Replication/Transcription Complex assay set-up to perform HTS campaigns under a 384 well plate formas, a universal standard in pharmaceutical companies and reserach laboratories.

D3.1 – A streaminlined and efficient drug discovery testing cascade for CoVs
Two drug discovery drug cascades have been developed within CARE, for different approaches:  target-based and  phenotypic approaches. These cascades show the critical assays that are needed to identify and validate Coronavirus antivirals.

D3.9 – Portfolio report (M6)
Report on the progress to deliver optimised small molecule candidate drugs to fight coronavirus, at month 6 (September 2020) of the project.

D3.10 – Portfolio report (M12)
Report on the progress to deliver optimised small molecule candidate drugs to fight coronavirus, at month 12 (March 2021) of the project.

D6.2 – Report on the suitability of mouse-adapted SARS-CoV-2 virus for lethal humanised ACE-2 model
SARS-CoV-2 uses human Angiotensin-Converting Enzyme (hACE2) as the entry receptor to bind and enter cells. The differences between the mouse and human receptor mean that inbred mice do not support high titre viral replication as mouse ACE2 does not effectively bind the viral spike protein. This report describes a method to modify the receptor-binding domain of the SARS-CoV-2 virus to improve binding to the mouse ACE2 receptor so that it can infect mouse cells via the mouse ACE2 receptor.

D6.3 – Report on reverse genetics system
This report describes a yeast-based synthetic genomics platform to genetically reconstruct diverse large RNA viruses, such as SARS-CoV-2. This technic facilitates rapid response to emerging viruses as it enables the real-time generation and functional characterisation of evolving RNA virus variants during an outbreak.

IMI & COVID-19 IMI-funded projects

IMI is Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

For further details please visit: imi.europa.eu

IMI has funded seven other projects fighting COVID-19 in Spring 2020:

  • COVID-RED: COVID-19 infections – Remote Early Detection
  • DECISION: A miniaturized disposable molecular diagnostics platform for combatting coronavirus infections
  • DRAGON: Rapid and secure AI imaging based diagnosis, stratification, follow-up, and preparedness for coronavirus pandemics
  • Impentri: Development of an intravenous imatinib formulation for COVID-19 acute respiratory distress syndrome (ARDS)
  • KRONO: Evaluation of a production ready portable, point-of-need platform (instrument and reagents), direct from nasal swab test for the molecular diagnostic detection of COVID-19 infection
  • MAD-CoV 2: Modern approaches for developing antivirals against SARS-CoV-2
  • RAPID-COVID: Robust automation and point of care identification of COVID